Atlas Trials

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

Clinical trial NCT03794440 · UNKNOWN

Trial details

NCT number
NCT03794440
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Status
UNKNOWN
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2019-02-11
Primary completion
2022-12-01
Enrollment
595

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.